We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App

Illumina Introduces Its Most Powerful and Sustainable Sequencer Yet at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: The NovaSeq X Plus system revolutionizes human whole-genome sequencing (Photo courtesy of Illumina)
Image: The NovaSeq X Plus system revolutionizes human whole-genome sequencing (Photo courtesy of Illumina)

Illumina Inc. (San Diego, CA, USA) is introducing the NovaSeq X Plus, its most powerful and most sustainable sequencer yet, at the 22nd edition of Medlab Middle East Congress which is taking place live, in-person from 6-9 February 2023.

The NovaSeq X Plus system is the most powerful and most sustainable sequencer from Illumina and enables laboratories to complete their most ambitious ultra-high-throughput projects. Labs can scale their studies with three flow cell types and up to 16 Tb output per run on the dual flow cell NovaSeq X Plus system or up to 8 Tb on the single flow cell NovaSeq X system. Ultra-high-density flow cells and ultra-high-resolution optics enable output of up to 26 billion single reads per flow cell. XLEAP-SBS chemistry delivers the highest level of data accuracy and performance, and the increased stability enables remarkable sustainability benefits. The DRAGEN Bio-IT Platform, available onboard or in the cloud, provides award-winning accuracy for rapid, easy-to-use, and efficient genomic data analysis.

At Medlab Middle East 2023, Illumina is also demonstrating the NextSeq 1000 and NextSeq 2000 sequencing platforms that are redesigned from the ground up. Their flexibility, affordability, and scalability help both new and experienced users achieve fast turnaround times and reduced operating costs. With the wide range of available flow cells, they support a variety of applications including single-cell gene expression, special transcriptomics, whole-exome sequencing, total RNA sequencing, shotgun metagenomics and infectious disease testing.

Additionally, Illumina is holding a half-day workshop on Genomics for Rare Diseases in the Middle East, featuring the latest findings related to the genomic basis of rare diseases and providing powerful insights into disease mechanisms and therapeutic approaches. As genomic sequencing becomes more available in the hospital setting, the expert panel discussion will be examining standardization, drivers & local challenges to implementation of genomic sequencing and how this is changing clinical practice. The program consists of scientific presentations from top experts in rare diseases, diagnostics and targeted testing followed by Q&A sessions. Guest speakers will be joining panel discussion with Illumina experts to identify the research, regulatory and access policy drivers to enable integration of whole genome sequencing into a healthcare setting.

Related Links:
Illumina Inc.

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.